Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The effect of donepezil treatment on cardiovascular mortality.

Literature DB >> 20664535

The effect of donepezil treatment on cardiovascular mortality.

K Sato¹, R Urbano, C Yu, F Yamasaki, T Sato, J Jordan, D Robertson, A Diedrich.

Abstract

The acetylcholinesterase inhibitor donepezil hydrochloride improves cognitive function in patients with Alzheimer's disease and vascular dementia. Given acetylcholine's important actions on the heart, we undertook a retrospective cohort investigation to assess whether donepezil usage affects cardiovascular mortality. In patients treated with donepezil, hazard ratios for total and cardiovascular mortality were 0.68 (P = 0.045, 95% confidence interval 0.46-0.99) and 0.54 (P = 0.042, 95% confidence interval 0.30-0.98), respectively. The apparent survival benefit in donepezil-treated patients should not be overinterpreted. Prospective clinical trials are warranted.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20664535 PMCID： PMC3120840 DOI： 10.1038/clpt.2010.98

Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875

28 in total

1. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials.

Authors: A Peter Passmore; Anthony J Bayer; Elisabeth Steinhagen-Thiessen
Journal: J Neurol Sci Date: 2005-01-06 Impact factor: 3.181

2. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?

Authors: Mason C Gasper; Brian R Ott; Kate L Lapane
Journal: Am J Geriatr Pharmacother Date: 2005-03

3. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.

Authors: Secundino López-Pousa; Josep Garre Olmo; Joan Vilalta Franch; Antoni Turon Estrada; Olga Soler Cors; Imma Pericot Nierga; Esther Gelada-Batlle
Journal: Age Ageing Date: 2006-07 Impact factor: 10.668

4. Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1alpha.

Authors: Yoshihiko Kakinuma; Motonori Ando; Masanori Kuwabara; Rajesh G Katare; Koji Okudela; Masanobu Kobayashi; Takayuki Sato
Journal: FEBS Lett Date: 2005-04-11 Impact factor: 4.124

5. Efferent vagal nerve stimulation protects heart against ischemia-induced arrhythmias by preserving connexin43 protein.

Authors: Motonori Ando; Rajesh G Katare; Yoshihiko Kakinuma; Dongmei Zhang; Fumiyasu Yamasaki; Kazuyo Muramoto; Takayuki Sato
Journal: Circulation Date: 2005-07-05 Impact factor: 29.690

6. Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients.

Authors: Barbara Borroni; Chiara Agosti; Giuliana Martini; Roberta Volpi; Cristina Brambilla; Luigi Caimi; Monica Di Luca; Alessandro Padovani
Journal: J Neurol Sci Date: 2004-12-08 Impact factor: 3.181

7. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.

Authors: Philippe Bordier; Stephane Garrigue; Stephane Lanusse; Julien Margaine; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal: CNS Drugs Date: 2006 Impact factor: 5.749

8. Declining into failure: the age-dependent loss of the L-type calcium channel within the sinoatrial node.

Authors: Sandra A Jones; Mark R Boyett; Matthew K Lancaster
Journal: Circulation Date: 2007-03-05 Impact factor: 29.690

9. Cardiovascular effects of centrally injected tetrahydroaminoacridine in conscious normotensive rats.

Authors: V Savci; M S Gürün; S Cavun; I H Ulus
Journal: Eur J Pharmacol Date: 1998-04-03 Impact factor: 4.432

10. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat.

Authors: E Lazartigues; J L Freslon; T Tellioglu; C Brefel-Courbon; M Pelat; M A Tran; J L Montastruc; O Rascol
Journal: Eur J Pharmacol Date: 1998-11-13 Impact factor: 4.432

12 in total

1. Various Regulatory Modes for Circadian Rhythmicity and Sexual Dimorphism in the Non-Neuronal Cardiac Cholinergic System.

Authors: Shino Oikawa; Yuko Kai; Asuka Mano; Hisayuki Ohata; Takahiro Nemoto; Yoshihiko Kakinuma
Journal: J Cardiovasc Transl Res Date: 2017-05-11 Impact factor: 4.132

Review 2. Cardiovascular effects of drugs used to treat Alzheimer's disease.

Authors: Laurence Guy Howes
Journal: Drug Saf Date: 2014-06 Impact factor: 5.606

Review 3. Heart Failure and Cognitive Impairment: Clinical Relevance and Therapeutic Considerations.

Authors: Tuoyo O Mene-Afejuku; Monica Pernia; Uzoma N Ibebuogu; Shobhana Chaudhari; Savi Mushiyev; Ferdinand Visco; Gerald Pekler
Journal: Curr Cardiol Rev Date: 2019

4. Donepezil, anti-Alzheimer's disease drug, prevents cardiac rupture during acute phase of myocardial infarction in mice.

Authors: Mikihiko Arikawa; Yoshihiko Kakinuma; Takemi Handa; Fumiyasu Yamasaki; Takayuki Sato
Journal: PLoS One Date: 2011-07-05 Impact factor: 3.240